Skip to Main Content
TABLE 3

Duration of graft function after autoimmune challenge

Transplant type*MeanMediannIndividuals (days normal)
Unmodified 30 ± 8 33 19, 20, 26, 33, 33, 35, 35, 42 
Ad-LacZ 27 ± 12 30 10 7, 14, 20, 21, 29, 31, 32, 32, 35, 49 
Ad-MnSOD 45 ± 11§ 44 11 32, 34, 35, 36, 44, 44, 47, 48, 48, 53, 69 
Nontransplanted 31 ± 5 31 22 17, 26, 26, 28 (x3), 29, 30, 30, 31 (x3), 32 (x3), 33 (x3), 34, 36, 39, 40 
Transplant type*MeanMediannIndividuals (days normal)
Unmodified 30 ± 8 33 19, 20, 26, 33, 33, 35, 35, 42 
Ad-LacZ 27 ± 12 30 10 7, 14, 20, 21, 29, 31, 32, 32, 35, 49 
Ad-MnSOD 45 ± 11§ 44 11 32, 34, 35, 36, 44, 44, 47, 48, 48, 53, 69 
Nontransplanted 31 ± 5 31 22 17, 26, 26, 28 (x3), 29, 30, 30, 31 (x3), 32 (x3), 33 (x3), 34, 36, 39, 40 
*

Groups were unmodified (normal) islet grafts, islets infected with either Ad-LacZ or Ad-MnSOD (100 MOI), and animals that did not receive a transplant to serve as controls for the adoptive transfer of disease. Each graft consisted of 400 islets.

Mean graft survival time in days ± SD.

Days of euglycemia after autoimmune challenge for individuals of each transplant type. The day the animal was challenged with 20 million spleen cells from a diabetic NOD was considered day 0.

§

Mean function length of MnSOD-treated islet grafts is significant when compared with each of the control groups (P = 0.001).

Close Modal

or Create an Account

Close Modal
Close Modal